Skip to main content
Top
Published in: International Journal of Clinical Oncology 11/2019

01-11-2019 | Sarcoma | Original Article

Clinical results of carbon-ion radiotherapy with separation surgery for primary spine/paraspinal sarcomas

Authors: Yoshihiro Matsumoto, Akira Matsunobu, Kenichi Kawaguchi, Mistumasa Hayashida, Keiichiro Iida, Hirokazu Saiwai, Seiji Okada, Makoto Endo, Nokitaka Setsu, Toshifumi Fujiwara, Shingo Baba, Satoshi Nomoto, Yasuharu Nakashima

Published in: International Journal of Clinical Oncology | Issue 11/2019

Login to get access

Abstract

Purpose

To evaluate the clinical outcome of combination of carbon-ion radiotherapy with separation surgery (CIRT-SS) in patients with primary spinal/paraspinal sarcoma (PSPS) and epidural spinal cord compression (ESCC).

Methods

CIRT-SS was performed in 11 consecutive patients. Patients treated in the primary and salvage settings were categorized into Group A (n = 8) and Group B (n  = 3), respectively. Clinical results and imaging findings were collected, with a particular focus on ESCC grade, treatment-associated adverse events (AEs), and the locoregional control (LRC) rate and overall survival (OS).

Results

The median follow-up period from the start of CIRT-SS was 25 months (7–57 months). ESCC was improved by SS in all cases. No patients exhibited radiation-induced myelopathy (RIM), but three developed Grade 3 vertebral compression fracture (VCF) during follow-up. Locoregional recurrences were observed in four patients [Group A: 1 (12.5%), Group B: 3 (100%)]. Over the entire follow-up period, three patients developed distant metastases and two patients died. The 2-year LRC rate and OS were 70% and 80%, respectively.

Conclusion

CIRT-SS in the primary setting achieved acceptable LRC and OS without RIM in patients with PSPS and with ESCC. VCF was the most frequent AE associated with CIRT-SS.
Literature
1.
go back to reference Catton C, O'Sullivan B, Bell R et al (1996) Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 41:67–72CrossRef Catton C, O'Sullivan B, Bell R et al (1996) Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 41:67–72CrossRef
2.
go back to reference Matsunobu A, Imai R, Kamada T et al (2012) Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer 118:4555–4563CrossRef Matsunobu A, Imai R, Kamada T et al (2012) Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer 118:4555–4563CrossRef
3.
go back to reference Matsumoto K, Imai R, Kamada T et al (2013) Impact of carbon ion radiotherapy for primary spinal sarcoma. Cancer 119:3496–3503CrossRef Matsumoto K, Imai R, Kamada T et al (2013) Impact of carbon ion radiotherapy for primary spinal sarcoma. Cancer 119:3496–3503CrossRef
4.
go back to reference Grimm J, Sahgal A, Soltys SG et al (2016) Estimated risk level of unified stereotactic body radiation therapy dose tolerance limits for spinal cord. Semin Radiat Oncol 26:165–171CrossRef Grimm J, Sahgal A, Soltys SG et al (2016) Estimated risk level of unified stereotactic body radiation therapy dose tolerance limits for spinal cord. Semin Radiat Oncol 26:165–171CrossRef
5.
go back to reference Al-Omair A, Masucci L, Masson-Cote L et al (2013) Surgical resection of epidural disease improves local control following postoperative spine stereotactic body radiotherapy. Neuro-Oncology 15:1413–1419CrossRef Al-Omair A, Masucci L, Masson-Cote L et al (2013) Surgical resection of epidural disease improves local control following postoperative spine stereotactic body radiotherapy. Neuro-Oncology 15:1413–1419CrossRef
6.
go back to reference Husain ZA, Sahgal A, Chang EL et al (2017) Modern approaches to the management of metastatic epidural spinal cord compression. CNS Oncol 6:231–241CrossRef Husain ZA, Sahgal A, Chang EL et al (2017) Modern approaches to the management of metastatic epidural spinal cord compression. CNS Oncol 6:231–241CrossRef
7.
go back to reference Lockney DT, Shub T, Hopkins B et al (2017) Spinal stereotactic body radiotherapy following intralesional curettage with separation surgery for initial or salvage chordoma treatment. Neurosurg Focus 42:E4CrossRef Lockney DT, Shub T, Hopkins B et al (2017) Spinal stereotactic body radiotherapy following intralesional curettage with separation surgery for initial or salvage chordoma treatment. Neurosurg Focus 42:E4CrossRef
8.
go back to reference Moulding HD, Elder JB, Lis E et al (2010) Local disease control after decompressive surgery and adjuvant high-dose single-fraction radiosurgery for spine metastases. J Neurosurg Spine 13:87–93CrossRef Moulding HD, Elder JB, Lis E et al (2010) Local disease control after decompressive surgery and adjuvant high-dose single-fraction radiosurgery for spine metastases. J Neurosurg Spine 13:87–93CrossRef
9.
go back to reference Laufer I, Iorgulescu JB, Chapman T et al (2013) Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine 18:207–214CrossRef Laufer I, Iorgulescu JB, Chapman T et al (2013) Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine 18:207–214CrossRef
10.
go back to reference Pennicooke B, Laufer I, Sahgal A et al (2016) Safety and Local control of radiation therapy for chordoma of the spine and sacrum: a systematic review. Spine 41:S186–192CrossRef Pennicooke B, Laufer I, Sahgal A et al (2016) Safety and Local control of radiation therapy for chordoma of the spine and sacrum: a systematic review. Spine 41:S186–192CrossRef
11.
go back to reference Matsumoto Y, Shinoto M, Endo M et al (2017) Evaluation of risk factors for vertebral compression fracture after carbon-ion radiotherapy for primary spinal and paraspinal sarcoma. BioMed Res Int 2017:9467402PubMedPubMedCentral Matsumoto Y, Shinoto M, Endo M et al (2017) Evaluation of risk factors for vertebral compression fracture after carbon-ion radiotherapy for primary spinal and paraspinal sarcoma. BioMed Res Int 2017:9467402PubMedPubMedCentral
12.
go back to reference Terezakis SA, Lovelock DM, Bilsky MH et al (2007) Image-guided intensity-modulated photon radiotherapy using multifractionated regimen to paraspinal chordomas and rare sarcomas. Int J Radiat Oncol Biol Phys 69:1502–1508CrossRef Terezakis SA, Lovelock DM, Bilsky MH et al (2007) Image-guided intensity-modulated photon radiotherapy using multifractionated regimen to paraspinal chordomas and rare sarcomas. Int J Radiat Oncol Biol Phys 69:1502–1508CrossRef
13.
go back to reference DeLaney TF, Liebsch NJ, Pedlow FX et al (2009) Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 74:732–739CrossRef DeLaney TF, Liebsch NJ, Pedlow FX et al (2009) Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 74:732–739CrossRef
14.
go back to reference Imai R, Kamada T, Araki N, Working Group for Bone and Soft Tissue Sarcomas (2016) Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases. Int J Radiat Oncol Biol Phys 95:322–327CrossRef Imai R, Kamada T, Araki N, Working Group for Bone and Soft Tissue Sarcomas (2016) Carbon ion radiation therapy for unresectable sacral chordoma: an analysis of 188 cases. Int J Radiat Oncol Biol Phys 95:322–327CrossRef
15.
go back to reference Sahgal A, Ames C, Chou D et al (2009) Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys 74:723–731CrossRef Sahgal A, Ames C, Chou D et al (2009) Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys 74:723–731CrossRef
16.
go back to reference Choi D, Melcher R, Harms J et al (2010) Outcome of 132 operations in 97 patients with chordomas of the craniocervical junction and upper cervical spine. Neurosurg 66:59–65CrossRef Choi D, Melcher R, Harms J et al (2010) Outcome of 132 operations in 97 patients with chordomas of the craniocervical junction and upper cervical spine. Neurosurg 66:59–65CrossRef
17.
go back to reference DeLaney TF, Liebsch NJ, Pedlow FX et al (2014) Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol 110:115–122CrossRef DeLaney TF, Liebsch NJ, Pedlow FX et al (2014) Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol 110:115–122CrossRef
18.
go back to reference Fourney DR, Frangou EM, Ryken TC et al (2011) Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol 29:3072–3077CrossRef Fourney DR, Frangou EM, Ryken TC et al (2011) Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol 29:3072–3077CrossRef
Metadata
Title
Clinical results of carbon-ion radiotherapy with separation surgery for primary spine/paraspinal sarcomas
Authors
Yoshihiro Matsumoto
Akira Matsunobu
Kenichi Kawaguchi
Mistumasa Hayashida
Keiichiro Iida
Hirokazu Saiwai
Seiji Okada
Makoto Endo
Nokitaka Setsu
Toshifumi Fujiwara
Shingo Baba
Satoshi Nomoto
Yasuharu Nakashima
Publication date
01-11-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 11/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01505-y

Other articles of this Issue 11/2019

International Journal of Clinical Oncology 11/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine